Glenmede Trust CO Na Genmab A/S Transaction History

Glenmede Trust CO Na

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.13 - $30.27 $218,580 - $263,288	8,698 New	8,698 $218,000
Q4 2020 Feb 16, 2021	SELL	$33.66 - $40.76 $537,146 - $650,448	-15,958 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$33.07 - $38.68 $468,535 - $548,018	14,168 Added 791.51%	15,958 $583,000
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $14,837 - $25,078	740 Added 70.48%	1,790 $60,000
Q4 2019 Feb 12, 2020	BUY	$18.88 - $24.14 $1,132 - $1,448	60 Added 6.06%	1,050 $23,000
Q2 2019 Aug 13, 2019	BUY	$16.37 - $18.47 $2,455 - $2,770	150 Added 17.86%	990 $18,000
Q1 2019 May 14, 2019	BUY	$14.53 - $17.93 $7,265 - $8,965	500 Added 147.06%	840 $14,000
Q4 2018 Feb 14, 2019	BUY	$12.12 - $16.48 $3,272 - $4,449	270 Added 385.71%	340 $5,000
Q2 2018 Aug 15, 2018	BUY	$14.78 - $21.54 $1,034 - $1,507	70 New	70 $1,000
Q4 2017 Feb 15, 2018	SELL	$16.29 - $22.84 $472 - $662	-29 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$20.81 - $23.48 $603 - $680	29	29 $0

240

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.